Nuclear structure as a source of cancer specific biomarkers

There are few biomarkers that have been developed which have proven clinical utility for the detection and prognosis of cancer. Cancer is diagnosed today, in large part, by examining cells under the microscope and determining the shape and texture of the nucleus. The molecular underpinnings of this hallmark of cancer are the components of the nuclear matrix. Utilizing proteomics focused on this subset of proteins, biomarkers have been identified that are specific for cancer types including prostate, colon and bladder cancer. These cancer biomarkers now serve as the basis of assays which can specifically identify individuals with cancer by sampling their blood and/or urine. In addition, these may serve as potential therapeutic targeting or imaging approaches. J. Cell. Biochem. 104: 1988–1993, 2008. © 2007 Wiley‐Liss, Inc.

[1]  K. Pienta,et al.  Identification of nuclear matrix proteins in the cancer and normal rat prostate. , 1991, Cancer research.

[2]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[3]  R Berezney,et al.  Identification of a nuclear protein matrix. , 1974, Biochemical and biophysical research communications.

[4]  M. Becich,et al.  Bladder cancer-associated nuclear matrix proteins. , 1996, Cancer research.

[5]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[6]  D. Landsittel,et al.  Use of the novel marker BLCA-1 for the detection of bladder cancer. , 2005, The Journal of urology.

[7]  G. Bubley,et al.  Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Moss,et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer , 1989, The Lancet.

[9]  R. Haba,et al.  Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. , 2005, The Journal of urology.

[10]  G. Brenes,et al.  Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. , 2000, The Journal of urology.

[11]  J. Nelson,et al.  Evaluation of the effect of spinal cord injury on serum PSA levels. , 2000, Urology.

[12]  A W Partin,et al.  Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. , 1993, Cancer research.

[13]  R. Getzenberg,et al.  Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma. , 2006, Urology.

[14]  B. Konety,et al.  Functional Characterization of the Bladder Cancer Marker, BLCA-4 , 2004, Clinical Cancer Research.

[15]  T. Church,et al.  Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. , 1999, Journal of the National Cancer Institute.

[16]  M. Babjuk,et al.  Highly specific urine-based marker of bladder cancer. , 2005, Urology.

[17]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[18]  M. Becich,et al.  Identification of nuclear matrix protein alterations associated with renal cell carcinoma. , 1998, The Journal of urology.

[19]  G. Bubley,et al.  BIOLOGY OF PROSTATESPECIFIC ANTIGEN , 2003 .

[20]  R. Schoen,et al.  Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Getzenberg,et al.  Characterization of nuclear matrix protein alterations associated with renal cell carcinoma. , 2006, Urology.

[22]  R. Getzenberg,et al.  Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. , 2005, Cancer research.

[23]  R. Schoen,et al.  Identification of calreticulin as a nuclear matrix protein associated with human colon cancer , 2003, Journal of cellular biochemistry.

[24]  B. Konety,et al.  Nuclear structural proteins as biomarkers of cancer , 1999, Journal of cellular biochemistry.

[25]  D. Landsittel,et al.  Early identification of individuals with prostate cancer in negative biopsies. , 2004, The Journal of urology.

[26]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[27]  D. Chan,et al.  EPCA-2: a highly specific serum marker for prostate cancer. , 2006, Urology.

[28]  R. Schoen,et al.  Identification of nuclear matrix protein alterations associated with human colon cancer. , 2002, Cancer research.

[29]  J. Bond,et al.  Clinical evidence for the adenoma-carcinoma sequence, and the management of patients with colorectal adenomas. , 2000, Seminars in gastrointestinal disease.

[30]  D. Chan,et al.  Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. , 2007, Cancer research.